• Investors may be considering whether Vertex Pharmaceuticals at around US$447.54 per share is offering good value right now, or if most of the opportunity is already reflected in the price.
• The stock has been relatively steady recently, with returns of 3.0% over the past week, 4.7% over the past month, a slight decline of 1.0% year to date, and a 1.2% return over the last year, alongside multi year figures of 34.1% over three years and 113.2% over five years.
• Recent headlines have focused on Vertex Pharmaceuticals' role in biotech and its existing treatment portfolio, which helps frame how investors are thinking about its current share price. This context matters because any change in expectations around future treatments or competitive positioning can shift how the stock is valued, even without new earnings guidance.
• In this context, Vertex Pharmaceuticals currently holds a valuation score of 4/6, based on checks of whether the stock looks undervalued across several methods. The next sections will break down those approaches and outline a more rounded way to think about value beyond the headline metrics.

Approach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required return. It is essentially asking what all those future cash flows are worth in current dollars.

For Vertex Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $3.76b. Analysts provide detailed free cash flow estimates for the next few years and Simply Wall St then extends those projections further out. By 2030, projected free cash flow is $7.74b, with interim years stepping up from $4.85b in 2026 to higher levels through 2035.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about $807.84 per share. Compared with the current share price around $447.54, the DCF output suggests the stock is trading at roughly a 44.6% discount to this intrinsic value. This points to potential undervaluation on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 44.6%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Vertex Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see what investors are paying today for each dollar of current earnings, which can be easier to relate to than cash flow models. A higher P/E can sometimes reflect stronger growth expectations or lower perceived risk, while a lower P/E can point to more modest growth assumptions or higher risk.

Vertex Pharmaceuticals currently trades on a P/E of 26.18x. That is above the broader Biotechs industry average of 16.25x, but below the peer group average of 40.64x. Simply Wall St also calculates a Fair Ratio for Vertex Pharmaceuticals of 26.04x. This is the P/E level suggested by factors such as its earnings profile, industry, profit margins, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with peers or the industry because it attempts to align the multiple with the company’s own characteristics rather than assuming all biotechs should trade on the same P/E. Vertex Pharmaceuticals’ actual P/E of 26.18x is very close to the Fair Ratio of 26.04x. This points to the stock being priced broadly in line with these fundamentals on this measure.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Vertex Pharmaceuticals to the numbers by linking your view of its cystic fibrosis franchise, nephrology pipeline and earnings potential to a forecast and a Fair Value. You can then compare that Fair Value with today’s price, with the Community page showing how a more cautious view might align with a Fair Value around US$414 a share, while a very optimistic view might sit closer to US$641. All of this updates as new earnings, trial results or news arrive so you can quickly see whether your chosen Narrative still fits the stock’s current price.

For Vertex Pharmaceuticals, however, we will make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives:

Fair Value: US$641.00

Implied discount to this Narrative Fair Value relative to the current price: about 30.2%.

Assumed revenue growth used in this narrative: 15.7%.

• Assumes ALYFTREK and JOURNAVX quickly scale within cystic fibrosis and pain treatment, broadening revenue beyond the existing CF franchise.
• Sees gene editing and cell therapies such as CASGEVY and programs in type 1 diabetes and kidney disease as long term, high margin contributors.
• Leans on strong cash generation and the balance sheet to support higher R&D spending, acquisitions, and share buybacks while still targeting higher margins.

Fair Value: US$414.06

Implied premium to this Narrative Fair Value relative to the current price: about 8.1%.

Assumed revenue growth used in this narrative: 6.3%.

• Highlights pressure on drug pricing and reimbursement in the US and Europe as a risk for revenue and margins over time.
• Flags the cost and complexity of gene editing and cell therapies as potential limits on how wide CASGEVY and other newer treatments can be used.
• Points to a concentrated pipeline in rare diseases and rising competition as reasons earnings could be more volatile than headline numbers suggest.

If you want to see how these views translate into detailed earnings paths, risk checks, and Fair Value ranges, you can step through the full set of community Narratives next.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vertex Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.